Two Cases of Pathological Complete Response with Neoadjuvant Therapy for Advanced Rectal Cancer
Matsuda, C.; Danno, K.; Miyazaki, S.; Fujitani, K.; Kubota, M.; Motoori, M.; Nakatsuka, R.; Okumura, Y.; Nomura, M.; Nishimura, M.; Kitagawa, A.; Matsuura, N.; Fushimi, H.; Iwase, K.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 42(12): 2313-2315
2015
ISSN/ISBN: 0385-0684 PMID: 26805348 Document Number: 685477
We report the cases of 2 patients with advanced rectal cancer who achieved pathological complete response to treatment with preoperative therapy. Case 1 was a 72-year-old man diagnosed with cT3N1M0 advanced rectal cancer. Neoadjuvant chemoradiotherapy with S-1 (120 mg/day) and radiation (50 Gy/25 Fr) was administered. Eight weeks after the last chemoradiation therapy, we performed laparoscopic Hartmann's operation. Case 2 was a 59-year-old man diagnosed with cT4aN0M0 advanced rectal cancer. He was treated with XELOX plus bevacizumab as neoadjuvant chemotherapy. Four weeks after 4 courses of treatment, he underwent laparoscopic Mile's operation. Neoadjuvant therapy was performed without any complications, and a pathological complete response was achieved in both patients. These cases demonstrated that neoadjuvant therapy can be a promising option for locally advanced rectal cancer.